<DOC>
	<DOCNO>NCT02157922</DOCNO>
	<brief_summary>The purpose study assessment efficacy safety OligoG dry powder formulation , adult subject cystic fibrosis .</brief_summary>
	<brief_title>A Phase IIb Study OligoG Subjects With Cystic Fibrosis</brief_title>
	<detailed_description>The primary objective demonstrate efficacy inhale OligoG measure FEV1 , support secondary endpoint include Mucociliary Clearance , rheology , microbiology Quality-of-Life . The secondary objective 1 . To demonstrate safety tolerability inhale OligoG dry powder inhalation multiple dose administration ; 2 . To evaluate patient compliance treatment . The design randomize , double-blind , placebo-controlled , multi-center , cross-over phase II study . Mucociliary Cough clearance ( MCC ) exploratory endpoint subset 24 patient , Lung Clearance Index ( LCI ) exploratory endpoint another subset 20 patient .</detailed_description>
	<mesh_term>Fibrosis</mesh_term>
	<mesh_term>Cystic Fibrosis</mesh_term>
	<mesh_term>Alginic acid</mesh_term>
	<criteria>Male female confirm diagnosis cystic fibrosis define : 1 . Clinical feature consistent diagnosis CF AND Sweat chloride ≥60 mmol/L pilocarpine iontophoresis ; OR 2 . Genotypic confirmation CFTR mutation Aged 18 year older Positive microbiological finding Pseudomonas aeruginosa expectorate sputum cough swab within 24 month prior Screening FEV1 40 % 100 % At Screening clinical laboratory finding suggestive significant pulmonary illness , CF Female subject child bear potential sexually active male subject must use contraception Provision write informed consent Changes underlie therapy within 14 day prior Day 0 . Subjects must willing remain underlying stable therapy regimens duration study final followup visit . Changes physiotherapy technique schedule within 14 day prior Day 0 . Prohibited medication within 7 day prior Day 0 . Pulmonary exacerbation within 28 day Screening . Positive microbiological finding Burkholderia sp . expectorate sputum cough swab document within 12 month prior Screening . Lactose intolerance/milk allergy . Ongoing acute illness . Subjects must need outpatient visit , hospitalization require change therapy pulmonary disease Screening Day 0 . History , plan organ transplantation . Treatment Allergic bronchopulmonary aspergillosis ( ABPA ) . Requirement continuous ( 24 hour/day ) oxygen supplementation . Diagnosed G551Dmutation , currently concomitant treatment Ivacaftor ( Kalydeco ) . Concomitant administration inhale mannitol hypertonic saline within 7 day prior Day 0 ( Visit 2 ) . Initiation cycle , inhale tobramycin ( TOBI ) Colistin le 4 month prior Screening ( Visit 1 ) . Note : Chronic TOBI Colistin user allow participate study , subject recently initiate chronic TOBI Colistin least 2 cycle TOBI Colistin respectively precede 4 month enrol study . Treatment phase line antibiotic treatment . Concomitant use market antibiotic agent permit , provide subject willing remain regimen within 28 day immediately prior Day 0 entire duration study ( followup visit ) . Clinically significant abnormal finding haematology clinical chemistry . In addition , value ≥ 3 x upper limit normal exclude subject participate study . Subjects unable perform pulmonary function test accord ATS/ERS criterion . Pregnant breastfeed woman . A negative urine pregnancy test must demonstrate female childbearing potential ( Section 4.2.9 ) Screening . Subjects participate interventional clinical trial within 28 day prior Day 0 ( Visit 2 ) . Subjects document suspected , clinically significant , alcohol drug abuse . Current malignant disease ( exception basal cell carcinoma cervical neoplasia ) . Any serious active medical psychiatric illness , opinion Investigator , would interfere subject treatment , assessment , compliance protocol . DPI intolerance , active placebo For MCC site : Smoking . A negative Cotinine test must demonstrate Screening Subjects nonremovable metal object metal plate , screw etc head , neck , chest abdominal area Subjects participation study exceed limit total radiation exposure allow 12 month period ( 5 mSv ) , exceed 10 mSv three year period .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>August 2016</verification_date>
	<keyword>Cystic fibrosis</keyword>
	<keyword>mucolytic</keyword>
	<keyword>mucociliary clearance</keyword>
	<keyword>lung clearance</keyword>
</DOC>